Corporate Magazine 2012 - Boehringer Ingelheim

GLORIA-AF®Registry programme for patientswith atrial fibrillation56,00056,000 patients in over50 countries2,200Around 2,200 sites will contributedata to assess the comparativeeffectiveness of new oralanticoagulants.Epidemiological studiesEpidemiological studies based on realworlddata are critically important.They are often requested by authoritiesand are also increasingly used to determinewhether and how well therapiesare covered by public and commercialhealth insurers. Boehringer Ingelheimis keen to learn more about how treatmentswork in real-world settings.Epidemiological studies may be basedon newly collected or on existing data.While the former type allows exact assessmentof all clinically relevant data,they can be time and cost intensive. Incontrast, existing healthcare data (e. g.claims, electronic medical records –EMR) represent the routine care of allpatients and are less resource-intensive,but often lack detailed clinical informationand the necessary quality.Impact of epidemiological studiesBoth types of studies, based on newlycollected as well as on existing data,have their advantages and complementeach other. Together, they contributeto the totality of evidence. Two examplesrelated to pradaxa® help to elucidatethis.Collecting new data – GLORIA-AF®The Registry Programme on Long-Term Oral Antithrombotic Treatmentin Patients with Atrial Fibrillaiton(GLORIA-AF®) was initiated byBoehringer Ingel heim and is scheduledto collect data from up to 56,000 patientsin over 50 countries. Around 2,200 siteswill contribute data to assess the comparativeeffectiveness of new oral anticoagulants.Until data become available,additional database studies will give initialinsights into pradaxa® treatmentsin real-world settings.Analysis of existing dataBefore pradaxa® was launched, astudy based on electronic medicalrecords was undertaken to better understandthe target population, theircharacteristics and comorbidities. Thisprovided important insights into the46 Boehringer Ingelheim annual report 2012